Endo International plc (ENDP)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

100 ENDO BOULEVARD CHADDS FORD, PA 19317

Develops and markets a portfolio of branded and generic pharmaceutical products primarily for the treatment of pain, including Percocet and Percodan. The company's products are marketed primarily to wholesale drug distributors and chain and independent retail pharmacists.

Data as of 2020-11-22
Market Cap1.198 Billion Shares Outstanding223.103 Million Avg 30-day Volume4.994 Million
P/E Ratio-7.5 Dividend Yield EPS-0.69
Price/Sales0.412 Price cash flow ratio4.5 Price free cash flow ratio5.8
Book Value-3.4 Price to Tangible Book-0.18 Alpha-0.03
Short Interest Ratio % Short Interest to Float R-squared0.067003
BETA1.31083 52-week High/Low7.1 / 2.08 Stddev0.213403
View SEC Filings from ENDP instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 0 1 (0.07%) 0 (0.0%)
Funds Holding: 176 193 -8.81% 41 (2.7%) 54 (3.5%) -24.07%
13F shares: 184.193 Million 184.357 Million -0.09% 63.068 Million 64.608 Million -2.38%
% Ownership 82.5593 82.6332 -0.09% 28.2684 28.959 -2.38%
New Positions: 22 32 -31.25% 5 13 -61.54%
Increased Positions 64 67 -4.48% 13 15 -13.33%
Closed Positions 36 21 71.43% 18 10 80.0%
Reduced Positions 53 57 -7.02% 12 18 -33.33%
Total Calls 1.826 Million 2.369 Million -22.9% 729.8 Thousand 1.202 Million -39.29%
Total Puts 1.252 Million 2.831 Million -55.78% 526.4 Thousand 1.555 Million -66.15%
PUT/CALL Ratio 0.69 1.2 -42.5% 0.72 1.29 -44.19%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ENDP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENDP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

APOSTOL GEORGE EVP, HEAD OF GLOBAL R&D

  • Officer
45,811 2020-11-04 1

CIARICO DOMENICO EVP & CHIEF COMMERCIAL OFFICER

  • Officer
55,958 2020-09-03 3

MALETTA MATTHEW JOSEPH EVP, CHIEF LEGAL OFFICER

  • Officer
204,383 2020-08-10 5

CAMPANELLI PAUL

  • Director
1,197,521 2020-08-10 4

COUGHLIN TERRANCE J EVP, CHIEF OPERATING OFFICER

  • Officer
356,644 2020-08-10 4

COLEMAN BLAISE PRESIDENT, CEO

  • Officer
  • Director
207,498 2020-08-10 4

BARRY PATRICK A EVP & PRES,GLOBAL COMM OPS

  • Officer
95,142 2020-08-10 4

GARELLA RAHUL EVP, INTL PHARMACEUTICALS

  • Officer
55,244 2020-08-10 4

BOYLE JACK D. SVP, CONTROLLER

  • Officer
36,538 2020-08-10 4

BRADLEY MARK T. EVP, CHIEF FINANCIAL OFFICER

  • Officer
36,351 2020-08-10 4

SMITH MARY CHRISTINE

  • Director
11,309 2020-07-29 4

MONTAGUE WILLIAM P

  • Director
106,137 2020-06-12 1

HYATT MICHAEL

  • Director
330,639 2020-06-12 1

KIMMEL ROGER H

  • Director
216,575 2020-06-12 1

HUTSON NANCY J

  • Director
91,219 2020-06-12 1

COOKE SHANE

  • Director
94,320 2020-06-12 1

BARBERIO MARK G

  • Director
13,266 2020-06-12 2

NICHOL CARRIE ANN SVP, CONTROLLER & CAO

  • Officer
14,096 2019-08-10 0

MANSUKANI SHARAD

  • Director
71,523 2019-06-12 0

PERA ANTONIO R PRESIDENT, PAR PHARMACEUTICAL

  • Officer
65,648 2019-04-02 0

RUDIO DANIEL SVP, CONTROLLER

  • Officer
9,669 2018-02-23 0

SMITH JILL D.

  • Director
43,719 2017-06-09 0

INGRAM DOUGLAS S

  • Director
17,336 2017-06-09 0

UPADHYAY SUKETU EVP, CHIEF FINANCIAL OFFICER

  • Officer
22,412 2016-09-24 0

CIAFFONI JOSEPH PRESIDENT, U.S. BRANDED PHARMA

  • Officer
17,452 2016-08-16 0

HIGGINS ARTHUR J

  • Director
50,623 2016-05-11 0

SISITSKY TODD BENJAMIN

  • Director
0 2016-05-05 0

VARGHESE HEMANTH JACOB PRES. INTERNATIONAL PHARMA

  • Officer
4,350 2016-04-29 0

DE SILVA RAJIV PRESIDENT & CEO

  • Officer
  • Director
355,010 2016-03-18 0

SPENGLER WILLIAM

  • Director
48,835 2016-03-17 0

HALL SUSAN EVP, CSO, GLOBAL HEAD OF R&D

  • Officer
4,826 2016-03-11 0

LORTIE BRIAN PRESIDENT BRANDED PHARMA

  • Officer
24,504 2016-03-02 0

MANOGUE CAROLINE B EXEC. V.P.,CHIEF LEGAL OFFICER

  • Officer
43,100 2015-04-07 0

FARHAT CAMILLE PRESIDENT, AMS, INC.

  • Officer
0 2015-03-10 0

DELUCCA JOHN

  • Director
32,343 2015-03-04 0

DEGOLYER DONALD W CHIEF OPERATING OFFICER,PHARMA

  • Officer
6,547 2015-02-26 0

GERGEL IVAN P. EVP, R&D AND CSO

  • Officer
27,649 2014-03-10 0

NASH DAVID

  • Director
11,859 2013-12-31 0

LEVIN ALAN G EVP, CHIEF FINANCIAL OFFICER

  • Officer
69,431 2013-06-01 0

SCODARI JOSEPH C

  • Director
6,515 2013-03-12 0

MCHUGH JULIE CHIEF OPERATING OFFICER

  • Officer
48,046 2013-03-08 0

HOLVECK DAVID PRESIDENT & CEO

  • Officer
  • Director
29,528 2013-02-26 0

SWEENEY EDWARD J PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2011-03-03 0

MEANWELL CLIVE

  • Director
11,855 2010-03-12 0

D. E. SHAW VALENCE PORTFOLIOS, L.L.C.

D. E. SHAW & CO, L.P.

SHAW DAVID E

  • 10% Owner
  • SEE FOOTNOTE 4.SEE FOOTNOTE 4.SEE FOOTNOTE 4.
No longer subject to file 2009-03-05 0

WYSENSKI NANCY CHIEF OPERATING OFFICER

  • Officer
13,054 2009-02-26 0

DE ROSEN MICHEL

  • Director
No longer subject to file 2008-06-30 0

HORNER GEORGE F III

  • Director
5,003 2008-03-12 0

ROWLAND CHARLES A JR EVP, CFO & TREASURER

  • Officer
6,699 2008-02-21 0

LEE DAVID A H EXEC. V.P AND CSO

  • Officer
2,801 2008-02-21 0

LAVISCOUNT JOYCE N CHIEF ACCOUNTING OFFICER

  • Officer
3,275 2008-02-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments